Leland Stanford Junior University

Visby Medical, Inc.

University of California

University of Colorado

Yale University

Colorado State University Research Foundation

Aeras Global Tb Vaccine Foundation

Gary K Schoolnik

Michael A Wilson

Marcel Behr

Peter Small

Victor Briones

Gregory Loney

David Swenson

Adam De La Zerda

Jonathan B Rothbard

Colin Kelly

Boris Andreyev

Ryan Cena

Joel M Palefsky

Peter O'Hanley

Lawrence Steinman

Jerald C Sadoff

David M Hone

Stanley Falkow

Amrit K Judd

Jorge R Oksenberg

Nicholas D Walter

Martin Voskuil

Gregory Dolganov

J Lucian Davis

Payam Nahid

Greg Robertson

Mario Alberto Flores-Valdez

Anne Lenaerts

Michel Klein

M Alexander Schmidt

David Lark

The present invention provides novel markers of treatment response in a subject infected with, which allow for quantifying treatment impact on the physiologic state of the

Methods of evaluating treatment efficacy and/or treatment duration in mycobacterial diseases

A method includes coupling a molecular diagnostic test device to a power source. A biological sample is conveyed into a sample preparation module. The device is then actuated by only a single action to cause the device to perform the following functions without further user action. First, the device heats the sample via a heater of the sample preparation module to lyse a portion of the sample. Second, the device conveys the lysed sample to an amplification module and heats the sample within a reaction volume of the amplification module to amplify a nucleic acid thereby producing an output solution containing a target amplicon. The device then reacts, within a detection module, each of (i) the output solution and (ii) a reagent formulated to produce a signal that indicates a presence of the target amplicon within the output solution. A result associated with the signal is then read.

Portable molecular diagnostic device and methods for the detection of target viruses

A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinantthat overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis.

[object Object]

Specific genetic deletion are identified in mycobacteria isolates, including variations in thegenome sequence between isolates, and numerous deletion present in BCG as compared to. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particularisolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted fromorto attenuate the pathogenic bacteria.

Specific genetic deletion are identified in mycobacteria isolates, including variations in thegenome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted fromorto attenuate the pathogenic bacteria.

Specific genetic deletions are identified in mycobacteria isolates, including variations in the genome sequence between isolates, and numerous deletion present in BCG as compared to . These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from or to attenuate the pathogenic bacteria.

Molecular differences between species of the M. tuberculosis complex

Specific genetic deletions are identified in mycobacteria isolates, including variations in the,genome sequence between isolates, and numerous deletion present in BCG as compared to,These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular,isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from,or,to attenuate the pathogenic bacteria.

A series of seventeen synthetic peptides which are capable of raising antibodies specific for certain desired human papilloma virus (HPV) are useful in diagnosis and therapy of conditions associated with HPV infection.

Diagnostic peptides of human papilloma virus

A novel method of defining oligopeptides is provided for determining useful immunodominant sequences for use as vaccines for pathogens. The method involves identifying sequences by particular selection procedures and using such sequences with antigen-presenting cells and T-cells to demonstrate activation of the common histocompatibility antigens DQ and DR in humans and their analogs in other animals. The oligopeptides may then be used individually or in combination to produce safe and effective vaccines, where genes may be prepared encoding the oligopeptides and used for expression of the oligopeptides or combinations of the oligopeptides or the gene transformed into the appropriate host, e.g., B. pertussis, for use as a vaccine to the intact organism.

Polypeptide pertussis toxin vaccine

A vaccine effective in protecting mammals against urinary tract infections is prepared from synthetic peptides substantially equivalent to short sequences contained in HU849 pilin conjugated to substantially antigenically neutral carriers or from a CNBrII fragment of HU849 pilin.

Synthetic vaccine against urinary infections

A vaccine effective in protecting mammals against urinary infections is prepared from purified Gal-Gal pilus proteins or fragments thereof.

Chemically defined vaccine against urinary infections

Vaccines comprising peptide sequences corresponding to immunorecessive determinants in gonorrhea pilus protein are disclosed. The vaccines are effective in protecting human subjects against infection by a wide range of gonorrhea strains by raising antibodies which interfere with the colonization of the epithelium by the infecting bacteria or which enhance phagocytosis.

Broad spectrum vaccine against gonorrhea

Vaccines comprising peptide sequences corresponding to immunorecessive determinants in gonorrhea pilus protein are disclosed. The vaccines are effective in protecting human subjects against infection by a wide range of gonorrhea strains by raising antibodies which interfere with the colonization of the epithelium by the infecting bacteria.

Growing community of inventors

Palo Alto, CA, United States of America

Gary K Schoolnik